Related Experiment Video

Updated: Oct 2, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.8K

Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients with Symptomatic Obstructive

Anjali T Owens1, Megan B Sutton2, Wei Gao3

  • 1Center for Inherited Cardiovascular Disease, Perelman Center for Advanced Medicine, University of Pennsylvania Perelman School of Medicine, 11th Floor South Tower, 3400 Civic Center Blvd, Philadelphia, PA, 19014, USA. anjali.owens@pennmedicine.upenn.edu.

Cardiology and Therapy
|March 1, 2022
PubMed

Insights

Treatment for obstructive hypertrophic cardiomyopathy (HCM) often changes, increasing healthcare costs. New, effective therapies are needed to manage the economic burden of this condition.

Area of Science:

  • Cardiology
  • Pharmacoeconomics
  • Health Services Research

Background:

  • Limited evidence exists on therapies for obstructive hypertrophic cardiomyopathy (HCM).
  • Data on treatment patterns and associated costs for obstructive HCM are scarce.
  • This study addresses the need for understanding treatment utilization and economic outcomes in symptomatic obstructive HCM patients.

Purpose of the Study:

  • To assess treatment patterns in patients with symptomatic obstructive HCM.
  • To evaluate healthcare resource utilization (HRU) and costs associated with obstructive HCM therapies.
  • To analyze treatment changes and their economic impact in obstructive HCM.

Main Methods:

  • Retrospective analysis of adults with symptomatic obstructive HCM from a large US claims database (2009-2019).
  • Patients were categorized by pharmacotherapies (beta blockers, calcium channel blockers, disopyramide) or procedures (septal reduction therapy, heart transplantation, ICD, pacemaker).
  • HRU, costs, and treatment modifications were assessed during a 12-month post-index treatment period.

Main Results:

  • 85% of 4883 patients received pharmacotherapies; 15.7% underwent procedures.
  • Mean total healthcare costs were $53,053, with procedures incurring higher HRU and costs.
  • Pharmacotherapy HRU varied, being lowest with beta blockers and highest with disopyramide; 43.8% of pharmacotherapy patients experienced treatment changes.

Conclusions:

  • High rates of treatment changes were observed in obstructive HCM patients.
  • The economic burden of obstructive HCM increases with escalating therapy.
  • Development of more effective therapies is crucial to stabilize or reduce the economic burden of obstructive HCM.
Abstract

Keywords:
Healthcare costsHealthcare resource utilizationObstructive hypertrophic cardiomyopathyTreatment change

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

553

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
78
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
55
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
45
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
47
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
77
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
64